Cocaine Use Disorder - Pipeline Insight, 2024

This “Cocaine Use Disorder - Pipeline Insight, 2024,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Cocaine Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Cocaine Use Disorder Understanding

Cocaine Use Disorder: Overview

Cocaine is a tropane ester alkaloid found in leaves of the Erythroxylum coca plant. Cocaine is the world's most addictive drug. Cocaine Use Disorder is a condition characterized by the harmful consequences of repeated cocaine use, a pattern of compulsive cocaine use, and (sometimes) physiological dependence on cocaine (i.e., tolerance and/or symptoms of withdrawal). Cocaine use increases the levels of the natural chemical messenger called dopamine in the brain and prevented from re-cycling, which causes extra amounts to build up between nerve cells and because of this “flood” of dopamine, the normal brain communication is interrupted and causes the high that people get from cocaine. Cocaine use can lead to addiction and adverse physical effects, such as stroke and cardiac arrest.

Symptoms
The symptoms of Cocaine Use Disorder include:

• Being unable to stop or limit use
• Craving cocaine
• Making a habit of using cocaine even though it causes problems
• Rapid increase in the amount of cocaine needed
• Regular use may result in irritability, exhaustion, nausea, vomiting, shaking, and sweating

Diagnosis
Diagnosis of Cocaine Use Disorder is done by thorough examination of patient’s symptoms and health history along with physical examination. The disorder is only diagnosed when cocaine use becomes persistent and causes significant academic, occupational, social or medical impairment. Accurate diagnosis of this disorder requires assessment by a qualified practitioner trained in psychiatric diagnosis and evidence-based treatment.

Treatment
The first step in the treatment for Cocaine Use Disorder is to stop using cocaine. This is also known as detox. The second step is to change behaviors to stop from using the drug again. Treatment may be given in a rehabilitation program. Medicines like antidepressants, Topiramate and gabapentin to lower the risk of seizures, Methylphenidate, Baclofen, Modafinil, or Disulfiram can be given to ease withdrawal symptoms and lower the risk of using again. Behavioral Therapy may be used for cocaine withdrawal.

Cocaine Use Disorder Emerging Drugs Chapters

This segment of the Cocaine Use Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cocaine Use Disorder Emerging Drugs

EMB-001: Embera NeuroTherapeuticsEMB-001 is a patented combination product comprised of two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. EMB-001 may potentially reduce the cravings and loss of control that drive relapse in addiction, by uniquely targeting multiple pathways, thereby possibly maximizing potential efficacy. The therapy is currently under Phase 2 clinical studies for cocaine use disorder and smoking cessation.

AFQ056: NovartisAFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist. AFQ056 has completed Phase II study in July 2021 (NCT03242928). The study has assessed whether AFQ056 can have a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.

Cocaine Use Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Cocaine Use Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cocaine Use Disorder

There are approx. 15+ key companies which are developing the therapies for Cocaine Use Disorder. The companies which have their Cocaine Use Disorder drug candidates in the most advanced stage, i.e. phase II include, Novartis.

Phases

This report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cocaine Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cocaine Use Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cocaine Use Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cocaine Use Disorder drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Cocaine Use Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Cocaine Use Disorder.

Cocaine Use Disorder Report Insights

• Cocaine Use Disorder Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cocaine Use Disorder Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cocaine Use Disorder drugs?
• How many Cocaine Use Disorder drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cocaine Use Disorder?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cocaine Use Disorder therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cocaine Use Disorder and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Embera NeuroTherapeutics
• Novartis
• Adapt Pharma
• Opiant Pharmaceuticals
• Camino Pharma
• EryDelga
• Orexigen Therapeutics
• NeuroSearch

Key Products

• EMB-001
• AFQ056
• Naloxone nasal spray
• SBP 0069330
• CoCe erythrocyte encapsulated - EryDel
• OREX-1019
• NS 2359

This product will be delivered within 2 business days.